Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Baxter
Moodys
Boehringer Ingelheim
Merck

Last Updated: August 19, 2022

Investigational Drug Information for GWP42003-P


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug GWP42003-P?

GWP42003-P is an investigational drug.

There have been 30 clinical trials for GWP42003-P. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2020.

The most common disease conditions in clinical trials are Syndrome, Epilepsy, and Seizures. The leading clinical trial sponsors are GW Research Ltd, University of Utah, and State of Georgia.

There is one US patent protecting this investigational drug and five international patents.

Recent Clinical Trials for GWP42003-P
TitleSponsorPhase
Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral NeuropathyNational Cancer Institute (NCI)Phase 2
Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral NeuropathyMayo ClinicPhase 2
Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic SeizuresJazz PharmaceuticalsPhase 3

See all GWP42003-P clinical trials

Clinical Trial Summary for GWP42003-P

Top disease conditions for GWP42003-P
Top clinical trial sponsors for GWP42003-P

See all GWP42003-P clinical trials

US Patents for GWP42003-P

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GWP42003-P See Plans and Pricing Pharmaceutical formulations GW Pharma Limited (Cambridge, GB) See Plans and Pricing
GWP42003-P See Plans and Pricing Compositions and methods for treating chronic inflammation and inflammatory diseases Infirst Healthcare Limited (London, GB) See Plans and Pricing
GWP42003-P See Plans and Pricing Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols KANNALIFE SCIENCES, INC. (Huntington, NY) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Baxter
Moodys
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.